Navigation Links
Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Date:9/2/2008

common symptoms of COPD are breathlessness (or a "need for air"), abnormal sputum (a mix of saliva and mucus in the airway), and a chronic cough. Daily activities, such as walking up a short flight of stairs or carrying a suitcase, can become very difficult as the condition gradually worsens(2). There are significant unmet needs in the treatment of COPD including limited therapeutic options to improve lung function and control exacerbations.

About aclidinium bromide and Genuair(R)

Aclidinium bromide is a novel, long-acting inhaled anticholinergic bronchodilator which has a long residence time at the M3 receptors and a shorter residence time at the M2 receptors. Aclidinium is rapidly hydrolyzed in human plasma to two major inactive metabolites. Forest Laboratories licensed US rights for aclidinium from Almirall, while Almirall maintains rights for the rest of the world. The companies are jointly involved in the development of the compound.

Aclidinium bromide is administered to patients using a novel, state-of-the-art multidose dry powder inhaler (MDPI), Genuair(R). Genuair(R) was designed with an intuitive feedback system, which through a 'coloured control window', an audible click and a slightly sweet taste indicates that the patient has inhaled correctly. The Genuair(R) inhaler contains 30 doses with a visible dose level indicator and also incorporates significant safety features such as an anti-double dosing mechanism and an end-of-dose lock-out system to prevent use of an empty inhaler.

About Forest Laboratories

Forest Laboratories (NYSE: FRX) is a US-based pharmaceutical company with a long track record of building partnerships and developing and delivering products that make a positive difference in people
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... DUBLIN , Aug. 4, 2015 /PRNewswire/ ... announced the addition of Jain PharmaBiotech,s new ... Markets, and Companies" to their offering. ... transdermal drug delivery - an approach used ... therapeutic use as an alternative to oral,intravascular, ...
(Date:8/4/2015)... York , August 4, 2015 ... titled " Non-invasive Prenatal Testing (NIPT) Market (BambniTest, Harmony, ... Others) - Global Industry Analysis, Size, Volume, Share, Growth, ... According to a new market report published by Transparency ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ...
(Date:8/4/2015)... Organovo Holdings, Inc. (NYSE MKT: ONVO; ... scientific and medical breakthroughs using 3D bioprinting technology, ... Paul Gallant as its General Manager of ... Gallant has more than 20 years of management ... most recently serving as chief operating officer for ...
Breaking Medicine Technology:Transdermal Drug Delivery Report 2015-2024 - Technologies, Markets, and Companies Analysis 2Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 2Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 3Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 4Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 5Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 2Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 3
(Date:8/4/2015)... St. Louis, Missouri (PRWEB) , ... August 04, ... ... Automated Texting (IAT) solutions, today announced that Bruce McCalley joins its executive leadership ... 30-year track record of sales success at technology companies and expanding global markets ...
(Date:8/4/2015)... ... , ... Montclair State University and Atlantic Health System have launched a new ... Jersey, which starting this Fall will help prepare those entering this burgeoning, hybrid field. ... System, one of the largest health care organizations in New Jersey, to design the ...
(Date:8/4/2015)... ... August 04, 2015 , ... It’s been called “cosmetics ... the customer experience inside Naimie’s Beauty Center in LA. Now MENAJI is part of ... look better. , Naimie’s Beauty Center has been a favorite of makeup artists and ...
(Date:8/4/2015)... (PRWEB) , ... August 04, ... ... its HealthCenter personal health record (PHR) product has achieved Office of the ... Inpatient EHR Certification from Drummond Group. HealthCenter delivers the highest quality personal ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... healthcare finance, announced the closing of a $118 million FHA-insured loan modification refinancing ... located in Smithfield and Clayton, North Carolina. JHSC is a joint venture ...
Breaking Medicine News(10 mins):Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 2Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 3Health News:MENAJI Shines in Make-Up Mecca for Stars 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 3Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3
... Additional beneficial effects on cardiometabolic risk factors beyond those ... drug rimonabant may not be due to the drug ... Drug and Therapeutics Bulletin (DTB). ,Advertisements ... Sanofi-Aventis) claim that an estimated 50% of the effects ...
... Cryo-Save Group NV together with the University of Cologne ... collect adult mesenchymal stem cells ("MSCs") from the ... allows the collection and cryopreservation of very high quantities ... ,Mesenchymal stem cells (MSCs) are of great therapeutic ...
... current rehab spell will bring a stop to her suicidal ... ,As the Mean Girls star checked into the Promises ... arrested for DUI, her supposed friends got ready to reveal ... America's Star magazine that Lohan attempted to take her own ...
... to enter rehab in order to get rid of his addiction ... was recently snapped in a sleazy romp with two hookers, admitted ... ,"Im a bad boy. I go out and get drunk, ... with the wrong women. Ive been sowing my oats for years, ...
... unabated across the Atlantic. But the man who set off ... Denver that specializes in the disease. The man himself ... Atlanta. He is not coughing, has no fever and does ... said. ,Still, staff at the National Jewish Medical ...
... double current funding levels for the President's Emergency Plan ... years after the program's original mandate expires next year, ... $15 billion over five years for HIV/AIDS and tuberculosis ... the Global Fund To Fight AIDS, Tuberculosis and Malaria. ...
Cached Medicine News:Health News:Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned 2Health News:Significant Scientific Breakthrough in Stem Cell Banking 2Health News:American Who Set Off TB Scare Doing Well in Hospital 2Health News:American Who Set Off TB Scare Doing Well in Hospital 3Health News:Bush Announces Request for $30B, Five-Year Extension of PEPFAR 2
... the latest technology and innovative software with ... transmission and auto detection of progressive lenses. ... network with the VELO 8500 Motorized Refractor ... the future. , ,*VELOtm Aculens 186UV can ...
...
...
...
Medicine Products: